These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Evidence of hypolipemiant and antioxidant properties of argan oil derived from the argan tree (Argania spinosa). Drissi A, Girona J, Cherki M, Godàs G, Derouiche A, El Messal M, Saile R, Kettani A, Solà R, Masana L, Adlouni A. Clin Nutr; 2004 Oct; 23(5):1159-66. PubMed ID: 15380909 [Abstract] [Full Text] [Related]
24. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Li JJ, Li YS, Chu JM, Zhang CY, Wang Y, Huang Y, Chen J, Yuan JQ, Huang YL. Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471 [Abstract] [Full Text] [Related]
25. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B. Arterioscler Thromb Vasc Biol; 2006 May; 26(5):977-86. PubMed ID: 16424352 [Abstract] [Full Text] [Related]
26. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. Field KM. Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181 [Abstract] [Full Text] [Related]
27. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R. Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546 [Abstract] [Full Text] [Related]
33. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E, PROVE IT-TIMI 22 Investigators. J Am Coll Cardiol; 2005 Oct 18; 46(8):1417-24. PubMed ID: 16226164 [Abstract] [Full Text] [Related]
34. C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis. Rosenau BJ, Costenbader KH, Schur PH. Vasc Med; 2008 Feb 18; 13(1):25-8. PubMed ID: 18372435 [Abstract] [Full Text] [Related]
35. Vasculoprotective potential of olive oil components. Carluccio MA, Massaro M, Scoditti E, De Caterina R. Mol Nutr Food Res; 2007 Oct 18; 51(10):1225-34. PubMed ID: 17912721 [Abstract] [Full Text] [Related]
38. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. Circulation; 2003 Sep 30; 108(13):1560-6. PubMed ID: 12975259 [Abstract] [Full Text] [Related]
39. [Atherosclerosis and arteriitis: implications for therapy of cardiovascular disease]. Galle J. Herz; 2004 Feb 30; 29(1):4-11. PubMed ID: 14968336 [Abstract] [Full Text] [Related]
40. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Undas A, Brozek J, Musial J. Clin Lab; 2002 Feb 30; 48(5-6):287-96. PubMed ID: 12071579 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]